一项多中心研究评估免疫检查点抑制剂在微卫星不稳定晚期非结直肠消化道肿瘤中的疗效
这项多中心回顾性研究纳入133例晚期错配修复缺陷/微卫星高度不稳定(dMMR/MSI-H)非结直肠消化道肿瘤患者,比较化疗与免疫检查点抑制剂(ICI)的疗效。经逆概率治疗加权(IPTW)调整后,ICI组无进展生存期(PFS)显著优于化疗组(HR=0.227;95%CI 0.147-0.351;p<0.0001),24个月PFS率分别为71.2%和7.9%,客观缓解率分别为60.7%和26.3%(p<0.001)。
要点
- 在晚期dMMR/MSI-H非结直肠消化道肿瘤中,ICI较化疗显著改善PFS(HR=0.227)。
- ICI组24个月PFS率为71.2%,化疗组为7.9%;客观缓解率分别为60.7%和26.3%。
- ICI疗效预测因素包括良好体力状况、无肝转移和既往原发肿瘤切除,原发部位无关。
核心结论
- 在缺乏随机试验的情况下,本研究强调ICI相比标准治疗在不可切除或转移性dMMR/MSI-H非结直肠消化道肿瘤中具有更优疗效,与肿瘤类型无关,毒性可接受。
研究设计与样本
- 多中心研究,回顾性纳入133例接受化疗和/或ICI治疗的晚期dMMR/MSI-H非结直肠消化道肿瘤患者,分为化疗组和免疫治疗(IO)组。
- 主要终点为无进展生存期(PFS),采用逆概率治疗加权(IPTW)法处理两组间潜在差异。
主要发现
- 133例患者中胃癌、小肠癌和其他癌分别占45.1%、27.1%和27.8%。
- 多数患者在一线(29.1%)或二线(44.4%)接受ICI治疗。
- 24个月PFS率化疗组为7.9%,IO组为71.2%。
- 经IPTW法,IO治疗与更好的PFS相关(HR=0.227;95%CI 0.147-0.351;p<0.0001)。
- 客观缓解率化疗组为26.3%,IO组为60.7%(p<0.001),IO组疾病控制持续时间延长(p<0.001)。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: One randomized phase III trial comparing chemotherapy (CT) with immune checkpoint inhibitors (ICI) has demonstrated significant efficacy of ICI in deficient DNA mismatch repair system/microsatellite instability-high (dMMR/MSI-H) metastatic colorectal cancer. However, few studies have compared ICI with CT in other advanced dMMR/MSI-H digestive tumors. METHODS: In this multicenter study, we included patients with advanced dMMR/MSI-H non-colorectal digestive tumors treated with chemotherapy and/or ICIs. Patients were divided retrospectively into two groups, a CT group and an immunotherapy (IO) group. The primary endpoint was progression-free survival (PFS). A propensity score approach using the inverse probability of treatment weighting (IPTW) method was applied to deal with potential differences between the two groups. RESULTS: 133 patients (45.1/27.1/27.8% with gastric/small bowel/other carcinomas) were included. The majority of patients received ICI in 1st (29.1%) or 2nd line (44.4%). The 24-month PFS rates were 7.9% in the CT group and 71.2% in the IO group. Using the IPTW method, IO treatment was associated with better PFS (HR=0.227; 95% CI 0.147-0.351; p < 0.0001). The overall response rate was 26.3% in the CT group versus 60.7% in the IO group (p < 0.001) with prolonged duration of disease control in the IO group (p < 0.001). In multivariable analysis, predictive factors of PFS for patients treated with IO were good performance status, absence of liver metastasis and prior primary tumor resection, whereas no association was found for the site of the primary tumor. CONCLUSIONS: In the absence of randomized trials, our study highlights the superior efficacy of ICI compared with standard-of-care therapy in patients with unresectable or metastatic dMMR/MSI-H non-colorectal digestive cancer, regardless of tumor type, with acceptable toxicity.
引用
- Moreau M, Alouani E, Flecchia C, et al. A multicenter study evaluating efficacy of immune checkpoint inhibitors in advanced non-colorectal digestive cancers with microsatellite instability. Eur J Cancer. 2024. PMID: 38537314. doi:10.1016/j.ejca.2024.114033
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。